Join
Live feed
·
PRReleasevia Quantisnow
Brickell Biotech Inc. logo

Brickell Biotech Acquires Exclusive Rights to Phase 1-Ready DYRK1A Inhibitor Program and Novel Platform Targeting Autoimmune and Inflammatory Diseases

ByQuantisnow·Wall Street's wire, on your screen.
BBI· Brickell Biotech Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track BBI (Brickell Biotech Inc.) and more on Quantisnow.